



São Paulo, May 07, 2024. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 1st quarter of 2024 (1Q24). The Company's parent company and consolidated financial statements for the periods ended March 31, 2024 and 2023 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of the previous year.

Our financial statements are prepared in accordance with IFRS 16. In order to better represent the economics of the business, the figures in this report are presented under IAS 17, the previous reporting standard. A reconciliation with IFRS 16 can be found in a dedicated chapter within this document.

In the 1Q24, we concluded the reclassification of certain revenues and expenses to ensure their maximum correlation with the Company's activities. These reclassifications refer to the results of 2023 and do not affect the EBITDA, balance sheet or cash flow. More details can be found in a dedicated chapter within this document.

CONSOLIDATED HIGHLIGHTS:

- **PHARMACIES: 3,010 units in operation (62 openings and 5 closures);**
- **GROSS REVENUE: R\$ 9.8 billion, a 15.3% increase with 6.9% of mature-store growth;**
- **MARKET SHARE: 16.2%, a 0.9 pp increase, with gains in every region;**
- **DIGITAL: R\$ 1.5 billion, an increase of 46.4% and a retail penetration of 17.3%;**
- **CONTRIBUTION MARGIN: 10.1% of gross revenues, an increase of 18.5%;**
- **ADJUSTED EBITDA: R\$ 679.9 million, an increase of 20.8% and a margin of 7.0%;**
- **ADJUSTED NET INCOME*: R\$ 213.7 million, a 4.8% increase and a margin of 2.2%;**
- **CASH FLOW: R\$ 118.1 million negative free cash flow, R\$ 179.3 million total cash consumption.**

* Reflects the taxation of the effects of investment subsidies in the calculation of income tax, in accordance with Law No. 14,789/2023. However, we have filed lawsuits questioning these effects and await their judgments, having received a partially favorable injunction so far.

RADL3
R\$ 26.33/share
 Closing: May 06, 2024

MARKET CAP
R\$ 45.2 billion

NUMBER OF SHARES
1,718,007,200


IR TEAM:
 Flávio Correia
 André Stolfi
 Victor Torres
 Felipe Correa

ir.rdsaude.com.br
ri@rd.com.br

Summary (R\$ thousands)	1Q23	2Q23	3Q23	4Q23	1Q24
# of pharmacies	2,746	2,807	2,868	2,953	3,010
Organic openings	55	64	64	87	62
Closures	(6)	(3)	(3)	(2)	(5)
Headcount (EoP)	53,495	55,239	57,295	57,691	57,708
Pharmacist count (EoP)	11,322	11,515	11,726	12,047	12,306
# of tickets (thousands)	84,906	91,152	91,261	94,401	95,846
# of active customers (MM)	48.1	47.5	46.4	47.6	48.2
Gross revenue	8,471,319	9,013,830	9,274,782	9,538,836	9,767,156
Growth (YoY)	+21.5%	+18.0%	+16.2%	+14.3%	+15.3%
Gross profit	2,314,784	2,600,421	2,578,822	2,670,232	2,659,264
% of gross revenue	27.3%	28.8%	27.8%	28.0%	27.2%
Adjusted EBITDA	562,981	767,625	658,097	614,544	679,885
% of gross revenue	6.6%	8.5%	7.1%	6.4%	7.0%
Adjusted net income	203,804	349,225	268,443	283,315	213,681
% of gross revenue	2.4%	3.9%	2.9%	3.0%	2.2%
Net income	206,426	363,154	296,570	284,651	212,995
% of gross revenues	2.4%	4.0%	3.2%	3.0%	2.2%
Free cash flow	(42,119)	(486,157)	336,224	150,930	(118,054)

STORE DEVELOPMENT


Pharmacy count



	1Q23	2Q23	3Q23	4Q23	1Q24	LTM
Gross openings	+55	+64	+64	+87	+62	+277
Closures	-6	-3	-3	-2	-5	-13
- Maturing	-1	-	-	-	-2	-2
- Mature	-5	-3	-3	-2	-3	-11
Net openings	+49	+61	+61	+85	+57	+264

Pharmacy portfolio

Age structure




We ended the 1Q24 with a total of 3,010 pharmacies, having opened 62 new units in the quarter and closed 5. We have celebrated the milestone of 3,000 pharmacies in operation with the opening of our first location in the city of Itapipoca, in the countryside of the state of Ceará.

We have opened 277 gross openings in the last 12 months and reiterate the guidance of 280 to 300 new units per year both for 2024 and 2025. At the end of the quarter, a total of 26.2% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.


Of the 5 closures in the quarter, only 2 were of pharmacies in the maturation process, equivalent to 0.7% of LTM openings, a result of the high assertiveness of our expansion process. The remaining 3 closures in the quarter were of mature units, with an average of 17 years of operation, as a consequence of the optimization of our pharmacy portfolio.

It is important to note that the closure of redundant stores allows us to transfer revenues to our remaining locations in the neighborhood while eliminating a full fixed-cost base and releasing assets to be more efficiently redeployed, thus increasing both the Company's EBITDA and ROIC. This combined plan of pharmacy openings and closures ensures an optimal portfolio of stores across the best corners of the country, expanding our physical presence, balancing the ideal density in each market, and, at the same time, maximizing the return on the assets employed.


Number of cities with pharmacies



Pharmacies by region




Pharmacies by format




We have continued to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 587 cities, 38 more than in the 1Q23, a unique capillarity in Brazilian retail. Of the 277 gross openings in the last 12 months, 73% occurred outside the state of São Paulo, our native market. Additionally, out of the 319 Brazilian cities with over 100 thousand inhabitants, we already have, or are in the process of opening, pharmacies in 308 of them. Lastly, 83% of our openings in the last 12 months have been of popular or hybrid formats, which already comprise 59% of our total store portfolio.

Geographic presence



Market share




We are present in all Brazilian states and operate 14 distribution centers that support our more than 3 thousand pharmacies. Our logistics network allows us to replenish 92% of our stores on a daily basis, improving service levels, optimizing working capital and reinforcing our operational efficiency, thus constituting an important competitive advantage.

In the 1Q24 we recorded market share gains in all regions. Our national share was of 16.2%, an annual increase of +0.9 pp. We recorded a market share of 28.2% in São Paulo (+1.3 pp), of 11.7% in the Southeast (+0.9 pp), of 19.9% in the Midwest (+1.3 pp), of 10.9% in the South (+0.9 pp), of 11.4% in the Northeast (+0.6 pp), and of 9.1% in the North (+1.1 pp).

DIGITAL HEALTH TRANSFORMATION


Digital sales and penetration*

R\$ millions, % of retail gross revenue




Digital channel mix

% of digital sales



Delivery mix

% of digital sales



* Considers reclassifications in 2023 from revenues to selling expenses.
 ** Call Center represents < 1% of the mix.

We continue to advance in our digital strategy. We reached R\$ 1,550.0 billion of revenues in our digital channels, a growth of 46.4% vs. the 1Q23. These channels reached a retail penetration of 17.3%, an increase of 3.7 pp in the period. We also recorded 132.0 million visits in our apps and websites in the quarter. Our customers who are both digitalized and frequent spend 27% more than non-digitized frequent customers, highlighting digitization as a key driver for value creation.

We also highlight the evolution of our app penetration in digital sales, which increased from 61% to 70% in the last 12 months, reaching a unique level of scale and relevance in the Brazilian pharmaceutical retail. Another highlight comes from deliveries in up to 60 minutes, which already represent 25% of digital sales. When combined with Click & Collect and deliveries by third-party apps, we have reached 92% of orders delivered or collected within 60 minutes, leveraging the unique capillarity of our footprint, which covers 93% of the Brazilian A class population living within a 1.5 km radius from our stores.

We achieved an NPS score of 90 in our pharmacies, in which the promotion of integral health has also advanced. We count almost 2 thousand health hubs offering an expanded services portfolio as well as 317 units licensed for vaccines. In the 1Q24, these pharmacies carried out 1.3 million pharmaceutical services, including 177 thousand CATs (clinical analysis tests), 48 thousand vaccinations and 1.1 million other services. Through these, we are repositioning our pharmacies as local health hubs and strengthening the bonds with our customers.

Lastly, we continue developing our Marketplace in order to offer an improved experience for our customers through a broadened assortment of 168 thousand SKUs in health and wellness categories offered by 736 different sellers.

➤ **ACCOUNTING RECLASSIFICATIONS**

In the 1Q24, we concluded the reclassification of certain revenues and expenses to ensure their maximum correlation with the Company's activities. In order to allow for a transparent analysis, we provide below a comparison of the 2023 results considering such reclassifications. It is important to highlight that these reclassifications do not affect our EBITDA, balance sheet or cash flow, being solely reallocations within our income statement.


The main change refers to the delivery fees charged to customers in digital sales and their corresponding deductions, which were reclassified from gross revenues to selling expenses, in which the costs related to these deliveries were always included (impact of 0.1 pp of gross revenues). Additionally, we reclassified the following general and administrative expenses to selling expenses (totaling 0.3 pp): marketing expenses related to the Drogasil and Raia banners and private labels (0.2 pp) and expenses with software licensing and cloud computing, which directly support sales, especially in the case of digital channels, among others (0.1 pp).

Consolidated R\$ millions	Originally presented					Variations						Reclassified values				
	1Q23	2Q23	3Q23	4Q23	2023	1Q23	2Q23	3Q23	4Q23	2023	% of GR	1Q23	2Q23	3Q23	4Q23	2023
Gross Revenue	8,479.0	9,024.7	9,288.3	9,557.4	36,349.4	(7.7)	(10.9)	(13.5)	(18.5)	(50.7)	(0.1 pp)	8,471.3	9,013.8	9,274.8	9,538.8	36,298.8
Deductions	(547.7)	(582.4)	(612.5)	(633.1)	(2,375.7)	0.7	1.2	2.2	3.4	7.6	0.0 pp	(546.9)	(581.2)	(610.3)	(629.7)	(2,368.1)
Net Revenue	7,931.3	8,442.3	8,675.8	8,924.3	33,973.8	(7.0)	(9.6)	(11.3)	(15.2)	(43.1)	(0.1 pp)	7,924.4	8,432.7	8,664.5	8,909.2	33,930.7
Gross Profit	2,321.7	2,610.1	2,590.1	2,685.4	10,207.4	(7.0)	(9.6)	(11.3)	(15.2)	(43.1)	(0.1 pp)	2,314.8	2,600.4	2,578.8	2,670.2	10,164.3
Selling Expenses	(1,471.2)	(1,523.2)	(1,598.3)	(1,712.9)	(6,305.6)	(13.5)	(20.8)	(15.8)	(13.7)	(63.8)	(0.2 pp)	(1,484.7)	(1,544.0)	(1,614.1)	(1,726.6)	(6,369.4)
G&A Expenses	(287.6)	(319.2)	(333.7)	(358.0)	(1,298.5)	20.5	30.4	27.1	28.9	106.9	0.3 pp	(267.1)	(288.8)	(306.6)	(329.1)	(1,191.6)
Adjusted EBITDA	563.0	767.6	658.1	614.5	2,603.2	-	-	-	-	-	-	563.0	767.6	658.1	614.5	2,603.2


Finally, we assume throughout this release the reclassified 2023 figures in order to avoid distortions in annual comparisons.

➤ **GROSS REVENUES**

We ended the 1Q24 with a gross revenue of R\$ 9,767 million, a growth of 15.3%. Our retail sales grew 15.0% in the 1Q24, with 4Bio contributing with 0.3 pp. Lastly, we recorded a positive calendar effect of just 0.2 pp, as the positive impact of the leap year was mitigated by the anticipation of the Easter holiday.




In the 1Q24, branded Rx recorded 12.6% of growth vs. 14.9% for Generics. The highlight of the quarter was HPC, with a growth of 20.0%. Finally, OTC grew 13.1%, despite the high comparison base which still includes revenues from products related to the COVID-19 pandemic.



In the 1Q24, we recorded a same store sales average growth of 9.6%, with 6.9% for mature stores, 1.3 pp above the CMED price readjustment of 5.6%, representing a normalization of real sales growth vs. the 4Q23.

↔ GROSS PROFIT




Gross profit totaled R\$ 2,659.2 million in the 1Q24, with a gross margin of 27.2%, a contraction of 0.1 pp vs. the 1Q23. Our retail gross margin was 29.0%, stable vs. the 1Q23, while 4Bio's growth generated a negative mix effect of 0.1 pp.

It is worth noting that, as of 1Q24, we started to consider in the results the additional charge of PIS/COFINS on tax subsidies related to investments, as established by Law No. 14,789/2023. This charge generated a pressure of 0.1 pp on the consolidated gross margin.

↔ SELLING EXPENSES

Selling expenses totaled R\$ 1,675.2 million in the 1Q24, equivalent to 17.2% of gross revenue and a dilution of 0.3 pp vs. the 1Q23, mainly due to the operational leverage derived from the real sales growth recorded in mature stores.


We recorded dilutions of 0.3 pp in personnel expenses and of 0.2 pp in rental expenses, more than offsetting the pressure of 0.1 pp in electricity expenses and 0.1 pp in other expenses.



* Considers reclassifications in 2023 from revenues and administrative expenses to selling expenses.

↔ CONTRIBUTION MARGIN

The contribution margin in the 1Q24 was R\$ 984.1 million, an increase of 18.5% over the 1Q23 and a margin expansion of 0.3 pp to 10.1% of gross revenue. This margin expansion was due to the dilution in sales expenses, more than offsetting the small pressure on the consolidated gross margin.




* Considers reclassifications in 2023 from revenues and administrative expenses to selling expenses.

↔ GENERAL & ADMINISTRATIVE EXPENSES

General and administrative expenses totaled R\$ 304.2 million in the 1Q24, equivalent to 3.1% of gross revenue. We recorded a sequential gain of 0.3 pp compared to the 4Q23, reflecting the good sales performance in the quarter combined with the Company's efforts to manage these expenses. Compared to the 1Q23, the dilution was of 0.1 pp.

General and administrative expenses*




* Considers reclassifications in 2023 from revenues and administrative expenses to selling expenses.

EBITDA

We reached an adjusted EBITDA of R\$ 679.9 million in the 1Q24, an increase of 20.8% compared to the 1Q23. The EBITDA margin was 7.0%, an expansion of 0.4 pp vs. the 1Q23, resulting from the expansion of contribution margin and the dilution in general and administrative expenses.

Adjusted EBITDA*



* Considers reclassifications in 2023 from revenues to selling expenses.


In retail, the EBITDA margin was 7.4%, also an expansion of 0.4 pp vs. the 1Q23.

EBITDA RECONCILIATION AND NON-RECURRING RESULTS

In the 1Q24, we recorded R\$ 1.0 million in net non-recurring expenses. This includes R\$ 2.1 million in social investments and donations and R\$ 1.8 million from tax effects and other expenses related to previous years, partially offset by R\$ 1.6 million in reversals of asset write-offs and R\$ 1.2 million in other non-recurring revenues.

EBITDA Reconciliation (R\$ millions)	1Q24	1Q23
Net income	213.0	206.4
Income tax	95.8	9.8
Equity Equivalence	(2.5)	2.4
Financial Result	155.5	159.7
EBIT	461.8	378.4
Depreciation and amortization	217.0	188.6
EBITDA	678.8	567.0
Social investments and donations	2.1	1.3
Tax effects and other non-recurring from previous years	1.8	(6.2)
Asset write-offs	(1.6)	0.9
Other non-recurring/non-operating effects	(1.2)	-
Non-recurring/non-operating expenses	1.0	(4.0)
Adjusted EBITDA	679.9	563.0

↔ **DEPRECIATION, NET FINANCIAL EXPENSES AND INCOME TAXES**



* Considers reclassifications in 2023 from revenues to selling expenses.
** Revaluation adjustment on participation in invested companies.


Depreciation expenses amounted to R\$ 217.0 million in the 1Q24, stable at 2.2% of gross revenue when compared to the 1Q23.

Net financial expenses represented 1.6% of gross revenues in the 1Q24, a reduction of 0.3 pp compared to the 1Q23. Of the R\$ 155.5 million, R\$ 78.8 million refer to the actual interests accrued on financial liabilities, equivalent to 0.8% of gross revenue, a 0.1 pp decrease when compared to the 1Q23 mainly due to the SELIC interest rate. We have also recorded R\$ 45.6 million in NPV adjustments, equivalent to 0.5% of gross revenue, a 0.1 pp decrease when compared to the 1Q23. Additionally, we provisioned R\$ 31.2 million related to the revaluation of the option to acquire the remaining shares of 4Bio Medicamentos S.A.. This share purchase happened on May 03rd 2024, increasing RD Saúde's stake to 100% of 4Bio's capital.

Finally, we booked R\$ 96.1 million in income taxes in the 1Q24, equivalent to 1.0% of gross revenue, an increase of 0.9 pp compared to 1Q23. This pressure was driven by changes in the taxing of investment subsidies upon income taxes, in accordance to Law No. 14,789/2023 (0.4 pp), one-off benefits from subsidies for investments in the 1Q23 (0.2 pp), and non-recurring taxes from previous year adjustments, the deferred tax connected to the surplus value of invested companies and other effects (0.3 pp).

It is worth noting the Company filed lawsuits questioning the effects of the new Law and awaits their judgement, having already received a partially favorable injunction.


↔ **NET INCOME**



Adjusted net income totaled R\$ 213.7 million in the 1Q24, a 4.8% growth in comparison to the 1Q23. The adjusted net margin was 2.2% of gross revenue, a 0.2 pp contraction in comparison to the same period of the previous year.

We highlight that the pressure of 0.1% of gross revenue incurred due to the increase in PIS/COFINS and of 0.9% in income tax were almost fully mitigated by operating gains in the quarter.

↔ **CASH CYCLE**



The cash cycle in the 1Q24 was of 60.4 days, an increase of 3.3 days compared to the 1Q23 and a sequential increase of 1.0 day in comparison to the 4Q23. This increase was mainly due to higher receivables, since the quarter ended during the Easter holiday.

⇨ CASH FLOW

Cash flow (R\$ millions)	1Q24	1Q23
Adjusted EBIT	462.9	374.4
NPV adjustment	(43.3)	(48.5)
Non-recurring expenses	(1.0)	4.0
Income tax (34%)	(142.3)	(112.1)
Depreciation	216.1	188.5
Others	(74.4)	20.9
Resources from operations	417.9	427.1
Cash cycle*	(307.2)	(173.2)
Other assets (liabilities)**	(35.4)	(68.2)
Operating cash flow	75.3	185.8
Investments	(193.3)	(227.9)
Free cash flow	(118.1)	(42.1)
M&A and other investments	(13.8)	(12.8)
Interest on equity and dividends	(0.2)	(0.0)
Net financial expenses***	(109.9)	(107.4)
Tax benefit (fin. exp., IoE, dividends)	62.7	63.7
Total Cash Flow	(179.3)	(98.7)

*Includes adjustments to discounted receivables.

**Includes NPV adjustments.

***Excludes NPV adjustments.

In the 1Q24, we recorded a negative free cash flow of R\$ 118.1 million, with a total cash consumption of R\$ 179.3 million. Resources from operations totaled R\$ 417.9 million, equivalent to 4.3% of gross revenue. We recorded a working capital consumption of R\$ 342,6 million, resulting in an operating cash flow of R\$ 75,3 million, which partially financed the CAPEX of R\$ 193.3 million.

Of the R\$ 193.3 million invested in the quarter, R\$ 97.7 million were used for the opening of new pharmacies, R\$ 45.0 million for the renovation or expansion of existing units, R\$ 38.0 million for IT, R\$ 9.1 million in logistics and R\$ 3.5 million in other projects. Additionally, we allocated R\$ 13.8 million into investments in subsidiaries.

Net financial expenses resulted in payments of R\$ 109.9 million in the 1Q24. These payments were partially offset by R\$ 62.7 million in tax benefits related to net financial expenses and interest on equity. Lastly, we provisioned R\$ 74,4 million in proceeds in interest on equity, compared to the R\$ 80.0 million provisioned in 1Q23.


⇨ INDEBTEDNESS

Net Debt (R\$ millions)	1Q23	2Q23	3Q23	4Q23	1Q24
Short-term Debt	443.8	569.8	581.0	604.6	311.9
Long-term Debt	1,832.6	1,833.8	2,523.5	2,526.1	2,528.0
Total Gross Debt	2,276.4	2,403.6	3,104.5	3,130.7	2,839.9
(-) Cash and Equivalents	371.3	345.3	593.6	412.3	412.6
Net Debt	1,905.1	2,058.3	2,510.9	2,718.4	2,427.3
Discounted Receivables	148.2	752.4	47.8	-	449.7
Advances to suppliers	(3.7)	-	(12.6)	(49.6)	(60.1)
Put/Call options of investments (estimated)	94.7	96.8	98.2	98.2	129.3
Adjusted Net Debt	2,144.3	2,907.4	2,644.3	2,766.9	2,946.3
Adjusted Net Debt / EBITDA	0.9x	1.2x	1.0x	1.1x	1.1x

We ended the 1Q24 with an adjusted net debt of R\$ 2,946.3 million, corresponding to a leverage of 1.1x the adjusted EBITDA of the last 12 months. Our adjusted net debt considers R\$ 449.7 million in discounted receivables, R\$ 60.1 million in advanced payments to suppliers, and R\$ 129.3 million in liabilities related to the put option granted and/or call option obtained for the acquisition of the remaining equity of invested companies.

At the end of the quarter, our gross debt totaled R\$ 2,839.9 million, of which 90.2% corresponds to debentures and Certificates of Real Estate Receivables (CRIs), with the remaining 9.8% corresponding to other credit lines. Of the total indebtedness, 89% is long-term, and 11% is short-term. We ended the quarter with a total cash and equivalents position of R\$ 412.6 million.

↔ **TOTAL SHAREHOLDER RETURNS**



Our share price decreased by 6.9% in the 1Q24, a decrease 2.4 pp greater than the 4.5% for the IBOVESPA. During the period, the average daily financial volume (ADTV) was of R\$ 214 million.

Since the IPO of Drogasil, we achieved a cumulative share appreciation of 2,344% vs. an appreciation of only 136% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 21.7%.

Considering the IPO of Raia in December of 2010, the cumulative return amounted to 877% vs. an increase of only 88% for the IBOVESPA. Considering the payment of interest on equity and dividends, this resulted in an average annual total return to shareholders of 19.2%.

↔ IFRS-16

Since 2019, our financial statements have been prepared in accordance with IFRS 16. In order to preserve historic comparability, the figures in this report are presented under IAS 17, the previous reporting standard, which we believe best represents the economic performance of our operations.

Financial statements in both IAS 17 and IFRS 16 are also available at our website ir.rdsaude.com.br under Results Spreadsheet.

Income Statement (R\$ millions)	1Q24		Change
	IAS 17	IFRS 16	Δ 1Q24
Gross Revenue	9,767.2	9,767.2	0.0
Gross Profit	2,659.3	2,659.3	0.0
Gross Margin	27.2%	27.2%	0.0 pp
Selling Expenses	(1,675.2)	(1,393.1)	282.1
G&A	(304.2)	(302.6)	1.6
Total Expenses	(1,979.4)	(1,695.6)	283.7
as % of Gross Revenue	20.3%	17.4%	(2.9 pp)
Adjusted EBITDA	679.9	963.6	283.7
as % of Gross Revenue	7.0%	9.9%	2.9 pp
Non-Recurring Expenses / Revenues	(1.0)	0.3	1.3
Depreciation and Amortization	(217.0)	(436.7)	(219.6)
Financial Results	(155.5)	(247.5)	(92.0)
Equity Equivalence	2.5	0.3	(2.2)
Income Tax	(95.8)	(86.8)	9.0
Net Income	213.0	193.3	(19.7)
as % of Gross Revenue	2.2%	2.0%	(0.2 pp)

Balance Sheet (R\$ millions)	1Q24		Change
	IAS 17	IFRS 16	Δ 1Q24
Assets	16,946.4	20,651.7	3,705.3
Current Assets	12,028.3	12,028.3	0.0
Non-Current Assets	4,918.1	8,623.4	3,705.3
Income Tax and Social Charges deferred	74.9	151.0	76.0
Other Credits	11.0	10.6	(0.4)
Right of use	0.0	3,629.7	3,629.7
Liabilities and Shareholder's Equity	16,946.4	20,651.7	3,705.3
Current Liabilities	7,511.5	8,386.4	874.8
Suppliers	5,592.4	5,599.0	6.6
Financial Leases	0.0	883.3	883.3
Other Accounts Payable	497.9	482.9	(15.0)
Non-Current Liabilities	2,978.4	6,120.3	3,141.9
Financial Leases	0.0	3,226.1	3,226.1
Income Tax and Social Charges Deferred	84.2	0.0	(84.2)
Shareholder's Equity	6,456.4	6,145.0	(311.5)
Income Reserves	1,871.2	1,577.4	(293.8)
Accrued Income	135.6	118.1	(17.5)
Non Controller Interest	73.4	73.3	(0.1)

Cash Flow (R\$ millions)	1Q24		Change
	IAS 17	IFRS 16	Δ 1Q24
Adjusted EBIT	462.9	527.0	64.1
Non-Recurring Expenses	(1.0)	0.3	1.3
Income Tax (34%)	(142.3)	(164.5)	(22.2)
Depreciation	216.1	436.7	220.5
Rental Expenses	0.0	(285.1)	(285.1)
Others	(74.4)	(53.1)	21.3
Resources from Operations	417.9	417.9	0.0
Operating Cash Flow	75.3	75.3	0.0
Investments	(193.3)	(193.3)	0.0
Free Cash Flow	(118.1)	(118.1)	0.0
Total Cash Flow	(179.3)	(179.3)	0.0

*Includes adjustments to discounted receivables.

**Includes NPV adjustments

***Excludes NPV adjustments

↔ RESULTS CONFERENCE CALLS

May 08th, 2024

Portuguese

at 10:00 (Brasília)

English

at 12:00 (Brasília)

Link

<https://www.resultadosrdsaude.com.br/>

For more information, please contact our Investor Relations department: ri@rd.com.br

Consolidated Adjusted Income Statement	1Q23	1Q24
(R\$ thousands)	Reclassified	
Gross Revenue	8,471,319	9,767,156
Taxes, Discounts and Returns	(546,933)	(666,662)
Net Revenue	7,924,386	9,100,494
Cost of Goods Sold	(5,609,602)	(6,441,230)
Gross Profit	2,314,784	2,659,264
Operational (Expenses) Revenues		
Sales	(1,484,700)	(1,675,213)
General and Administrative	(267,103)	(304,166)
Operational Expenses	(1,751,803)	(1,979,379)
EBITDA	562,981	679,885
Depreciation and Amortization	(188,602)	(217,017)
Operational Earnings before Financial Results	374,379	462,867
Financial Expenses	(250,952)	(258,093)
Financial Revenue	91,224	102,545
Financial Expenses/Revenue	(159,728)	(155,548)
Equity Equivalence	(2,382)	2,501
Earnings before Income Tax and Social Charges	212,269	309,820
Income Tax and Social Charges	(8,464)	(96,139)
Net Income	203,804	213,681

Consolidated Income Statement	1Q23	1Q24
(R\$ thousands)	Reclassified	
Gross Revenue	8,471,319	9,767,156
Taxes, Discounts and Returns	(546,933)	(666,662)
Net Revenue	7,924,386	9,100,494
Cost of Goods Sold	(5,609,602)	(6,441,230)
Gross Profit	2,314,784	2,659,264
Operational (Expenses) Revenues		
Sales	(1,484,700)	(1,675,213)
General and Administrative	(267,103)	(304,166)
Other Operational Expenses, Net	3,972	(1,039)
Operational Expenses	(1,747,831)	(1,980,419)
EBITDA	566,953	678,845
Depreciation and Amortization	(188,602)	(217,017)
Operational Earnings before Financial Results	378,351	461,828
Financial Expenses	(250,952)	(258,093)
Financial Revenue	91,224	102,545
Financial Expenses/Revenue	(159,728)	(155,548)
Equity Equivalence	(2,382)	2,501
Earnings before Income Tax and Social Charges	216,241	308,781
Income Tax and Social Charges	(9,815)	(95,786)
Net Income	206,426	212,995

Assets (R\$ thousands)	1Q23	1Q24
Current Assets		
Cash and Cash Equivalents	371,267	412,598
Financial Investments	992	-
Accounts Receivable	2,630,057	2,963,925
Inventories	6,791,082	7,677,322
Taxes Receivable	395,475	344,997
Other Accounts Receivable	315,951	497,297
Anticipated Expenses	112,042	132,113
	<u>10,616,865</u>	<u>12,028,251</u>
Non-Current Assets		
Deposit in Court	137,185	234,081
Taxes Receivable	128,056	229,598
Income Tax and Social Charges deferred	16,771	74,937
Other Credits	6,116	11,009
Investments	2,426	10,279
Property, Plant and Equipment	2,222,854	2,451,557
Intangible	1,749,274	1,906,678
	<u>4,262,681</u>	<u>4,918,139</u>
ASSETS	<u>14,879,546</u>	<u>16,946,390</u>
Liabilities and Shareholder's Equity (R\$ thousands)		
	1Q23	1Q24
Current Liabilities		
Suppliers	5,106,694	5,592,414
Loans and Financing	443,799	311,914
Salaries and Social Charges Payable	526,308	604,957
Taxes Payable	263,123	360,411
Dividend and Interest on Equity	131,995	87,395
Provision for Lawsuits	54,372	56,601
Other Accounts Payable	326,298	497,856
	<u>6,852,588</u>	<u>7,511,548</u>
Non-Current Liabilities		
Loans and Financing	1,832,601	2,527,999
Provision for Lawsuits	54,645	256,092
Income Tax and Social Charges deferred	148,311	84,211
Other Accounts Payable	227,337	110,126
	<u>2,262,894</u>	<u>2,978,428</u>
Shareholder's Equity		
Common Stock	2,500,000	4,000,000
Capital Reserves	115,466	145,372
Revaluation Reserve	11,313	11,179
Income Reserves	2,781,229	1,871,200
Accrued Income	120,644	135,603
Equity Adjustments	2,809	2,059
Non Controller Interest	65,076	73,402
Additional Dividend Proposed	167,526	217,598
	<u>5,764,064</u>	<u>6,456,414</u>
LIABILITIES AND SHAREHOLDERS' EQUITY	<u>14,879,546</u>	<u>16,946,390</u>

Cash Flow (R\$ thousands)	1Q23	1Q24
Earnings before Income Tax and Social Charges	216,401	212,995
Adjustments		
Depreciation and Amortization	188,541	216,110
Compensation plan with restricted shares, net	2,598	(1,708)
Interest over additional stock option	29,969	31,151
PP&E and Intangible Assets residual value	15,872	5,495
Provisioned Lawsuits	16,239	14,263
Provisioned Inventory Loss	(12,858)	1,613
Provision for Doubtful Accounts	1,334	2,804
Provisioned Store Closures	(2,474)	(3,281)
Interest Expenses	81,364	90,556
Debt Issuance Costs Amortization	1,321	1,913
Equity Equivalence Result	2,382	(340)
	540,689	571,571
Assets and Liabilities variation		
Clients and Other Accounts Receivable	(321,950)	118,210
Inventories	(652,168)	(481,508)
Other Short Term Assets	(100,826)	(113,295)
Long Term Assets	111,816	(1,180)
Suppliers	848,858	495,308
Salaries and Social Charges	(35,315)	(31,436)
Taxes Payable	(109,029)	60,415
Other Liabilities	36,734	90,352
Rents Payable	(1,690)	(1,046)
Cash from Operations	317,119	707,391
Interest Paid	(100,213)	(132,835)
Income Tax and Social Charges Paid	-	(101,031)
Paid lawsuits	(14,463)	(15,450)
Net Cash from (invested) Operational Activities	202,443	458,075
Investment Activities Cash Flow		
PP&E and Intangible Acquisitions	(240,719)	(211,376)
PP&E Sale Payments	-	4,194
Net Cash from Investment Activities	(240,719)	(207,182)
Financing Activities Cash Flow		
Funding	20,577	49,577
Payments	(44,552)	(300,000)
Interest on Equity and Dividends Paid	(23)	(194)
Net Cash from Funding Activities	(23,998)	(250,617)
Cash and Cash Equivalents in the beginning of the period	433,541	412,322
Cash and Cash Equivalents net increase	(62,274)	276
Cash and Cash Equivalents in the end of the period	371,267	412,598